

Appendix 2- ICU sub-analysis in patients with COVID-19 disease

Table 1 - Baseline characteristics: ICU subanalysis on patients with COVID-19 disease

Demographics	ICU	Ward	Total	p-value
Gender				0.03
Female	10 (36%)	41 (60%)	51 (53%)	
Male	18 (64%)	27 (39%)	45 (47%)	
Race				0.7
Asian	0 (0%)	1 (2%)	1 (1%)	
White	26 (93%)	64 (94%)	90 (94%)	
Black	2 (7%)	3 (4%)	5 (5%)	
ADL				0.01
Dependent	1 (4%)	17 (25%)	18 (19%)	
Independent	27 (96%)	51 (75%)	78 (81%)	
Age	68 (8.5)	73 (13)	71 (12)	0.06
Comorbidities				
COPD	1 (4%)	4 (6%)	5 (5%)	0.6
Asthma	0 (0%)	3 (4%)	3 (3%)	0.2
Heart failure	2 (7%)	17 (25%)	19 (20%)	0.04
Diabetes Mellitus	13 (46%)	22 (32%)	35 (36%)	0.1
Cirrhosis	2 (7%)	1 (1%)	3 (3%)	0.1
Kidney failure	3 (11%)	11 (16%)	14 (15%)	0.5
Obesity	8 (28%)	13 (19%)	21 (22%)	0.3
Neoplasia	3 (11%)	4 (6%)	7 (7%)	0.4
Solid organ transplant	2 (7%)	2 (3%)	4 (4%)	0.3
Immunosuppression	4 (14%)	9 (13%)	13 (13%)	0.9
Severity				<0.001
Moderate	0 (0%)	9 (13%)	9 (9%)	
Severe	5 (18%)	59 (87%)	64 (66%)	
Critical	23 (82%)	0 (0%)	23 (24%)	
N	28	68	96	

ADL: Activities daily-living; COPD: Chronic obstructive pulmonary disease; ICU: Intensive care unit

Table 2 - COVID-19 fog persistent symptoms and quality of life (index, VAS and difference): ICU sub-analysis on patients with COVID-19 disease

COVID-19 fog persistent symptoms	ICU	Ward	Total	p-value
Fatigue	18 (32%)	38 (68%)	56 (58%)	0.4
Mood changes	15 (54%)	15 (22%)	30 (31%)	0.002
Headache	10 (30%)	23 (69%)	33 (34%)	0.8
Attention disturbances	17 (61%)	22 (56%)	39 (41%)	0.01
Insomnia	14 (50%)	34 (50%)	48 (50%)	1
Memory impairment	17 (51%)	32 (65%)	49 (51%)	0.2
EQ-5D-5L				
Index before COVID-19	0.85 (0.2)	0.8 (0.2)	0.8 (0.2)	0.4
Index after COVID-19	0.76 (0.27)	0.7 (0.3)	0.7 (0.3)	0.49
Index difference	-0.08(0.1)	-0.1 (0.2)	-0.09 (0.19)	0.6
VAS				
VAS before COVID-19	73.4 (20)	73 (18)	73(19)	0.9
VAS after COVID-19	65 (22)	63 (21)	63 (21)	0.7
VAS difference	-8.9 (22)	-9.7 (15)	-9.5 (17)	0.8

ICU: Intensive care unit; VAS: Visual analogue scale